Abstract:BACKGROUND:Despite the World Health Organization listing methadone as an essential medication, effective dose selection is challenging, especially in racial and ethnic minority populations. Subtherapeutic doses can result in withdrawal symptoms while supratherapeutic doses can result in overdose and death. Although CYP3A4 was conventionally considered the principal methadone metabolizing enzyme, more recent data have identified CYP2B6 as the principal enzyme. CYP2B6 has ethnically-associated polymorphisms that affect the metabolic rate. Our objective was to investigate the effects of genetic and nongenetic factors on methadone metabolism.METHODS:We measured trough plasma methadone levels in 100 participants with opioid use disorder. We assessed methadone metabolism by calculating the metabolite ratio (major metabolite: 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine [EDDP] divided by methadone concentration). We assessed hepatic fibrosis and steatosis by transient elastography and CYP2B6 alleles, principally responsible for methadone metabolism. Mixed effects models modeled the data in 97 participants.RESULTS:Participants were largely male (58%), minority (61% African American) and non-Hispanic (68%). Forty percent were HCV mono-infected, 40% were uninfected, and 20% were HCV/HIV co-infected. Female sex had significant effects on (R)- and (S)-methadone metabolism (p = 0.016 and p = 0.044, respectively). CYP2B6 loss of function (LOF) alleles significantly affected (S)-methadone metabolism (p = 0.012). Body mass index (BMI) significantly affected (R)-methadone metabolism (p = 0.034). Methadone metabolism appeared to be lower in males, in individuals with LOF alleles, and elevated BMI.CONCLUSIONS:Genetic analysis, especially in minority populations, is essential to delivering individualized treatments. Although the principal methadone metabolizing enzyme remains controversial, our results suggest that sex, CYP2B6 genotype, and BMI should be incorporated into multivariate models to create methadone dosing algorithms. Methadone dosing algorithms should facilitate medication delivery, improve patient satisfaction, and diminish overdose potential.

Effects of CYP2C19 variants on methadone metabolism in vitro.

In Vitro Assessment of 24 CYP2D6 Allelic Isoforms on the Metabolism of Methadone.

Effects of CYP3A4 Variants on Methadone Metabolism In Vitro

Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 Ons-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation

Effects of CYP2C19 variants on the metabolism of tapentadol in vitro

The Effects Of Cytochrome P450 2c19 Polymorphism On The Metabolism Of Voriconazole In Vitro

Evaluation of the Effects of 18 Non-Synonymous Single-Nucleotide Polymorphisms of CYP450 2C19 on in Vitro Drug Inhibition Potential by a Fluorescence-Based High-Throughput Assay.

Effects of 31 Recombinant CYP2C19 Variants on Clomipramine Metabolism in Vitro

Toward Precision Prescribing for Methadone: Determinants of Methadone Deposition.

Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro

Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis

Effect of CYP2C9 Genetic Polymorphism on the Metabolism of Flurbiprofen in Vitro.

Association between genetic polymorphism of CYP3A4, CYP2D6 and response to methadone maintenance treatment

Effects of CYP2C19 Variants on Fluoxetine Metabolism in Vitro.

Frequency of CYP2D610 and 14 Alleles and Their Influence on the Metabolic Activity of CYP2D6 in a Healthy Chinese Population

Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance.

In Vitro Functional Analysis of 24 Novel Cyp2c19 Variants Recently Found in the Chinese Han Population

Genetic Polymorphisms and Phenotypic Analysis of Drug-Metabolizing Enzyme CYP2C19 in a Li Chinese Population.

Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms in Vitro

In Vitro Functional Characterization of 37 CYP2C9 Allelic Isoforms Found in Chinese Han Population.

Characterization of 15 CYP2J2 variants identified in the Chinese Han population on the metabolism of ebastine and terfenadine in vitro